青光眼与高眼压激光治疗(LiGHT)试验:多中心随机对照试验的设计与方法学
LiGHT试验为前瞻性、非设盲、多中心、实用性随机对照试验,2012至2014年间在英国六家合作中心招募718例既往未经治疗的原发性开角型青光眼(POAG)或高眼压症(OHT)患者,比较初始选择性激光小梁成形术(SLT)与初始局部降眼压药物治疗。主要结局为健康相关生活质量(EQ-5D五水平),随访3年,按意向性治疗分析。
要点
- LiGHT试验旨在验证初始SLT是否优于初始局部药物治疗POAG或OHT。
- 718例既往未经治疗患者随机分入初始SLT组或单纯药物治疗组,随访3年。
- 主要结局为EQ-5D五水平健康相关生活质量,次要结局包括成本效果与安全性等。
核心结论
- LiGHT试验将提供SLT与局部降眼压药物在健康相关生活质量、临床有效性和成本效果方面的有价值数据。
研究设计与样本
- 前瞻性、非设盲、多中心、实用性随机对照试验。
- 2012至2014年间在英国六家合作中心招募718例既往未经治疗的POAG或OHT患者。
- 试验设两个治疗组:初始SLT后按需联合常规药物治疗,以及不使用激光的药物治疗。
- 通过基于网络的随机化服务在线进行随机化。
- 参与者按常规临床实践随访3年。
主要发现
- 原文为试验设计和方法学报告,未报告结局数据。
关键数值与推荐
- 主要结局指标为健康相关生活质量(EQ-5D五水平)。
- 次要结局包括治疗路径成本与成本效果、青光眼效用指数、青光眼症状量表、青光眼生活质量、路径有效性的客观测量、视觉功能与安全性特征及依从性。
- 基线时根据算法设定目标眼压,算法基于疾病严重程度和招募时终生视力丧失风险,随后根据眼压控制、视盘和视野进行调整。
- 试验注册号为ISRCTN32038223,Pre-results。
临床怎么用
- 原文为试验设计报告,未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial aims to establish whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for primary open-angle glaucoma (POAG) or ocular hypertension (OHT). DESIGN: The LiGHT Trial is a prospective, unmasked, multicentre, pragmatic, randomised controlled trial. 718 previously untreated patients with POAG or OHT were recruited at six collaborating centres in the UK between 2012 and 2014. The trial comprises two treatment arms: initial SLT followed by conventional medical therapy as required, and medical therapy without laser therapy. Randomisation was provided online by a web-based randomisation service. Participants will be monitored for 3 years, according to routine clinical practice. The target intraocular pressure (IOP) was set at baseline according to an algorithm, based on disease severity and lifetime risk of loss of vision at recruitment, and subsequently adjusted on the basis of IOP control, optic disc and visual field. The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma Quality of Life, objective measures of pathway effectiveness, visual function and safety profiles and concordance. A single main analysis will be performed at the end of the trial on an intention-to-treat basis. CONCLUSIONS: The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide valuable data on the relative HRQL, clinical effectiveness and cost-effectiveness of SLT and topical IOP-lowering medication. TRIAL REGISTRATION NUMBER: ISRCTN32038223, Pre-results.
引用
- Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology. Br J Ophthalmol. 2017. PMID: 28903966. doi:10.1136/bjophthalmol-2017-310877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。